Please login to the form below

Not currently logged in
Email:
Password:

Sepracor and Eisai partner to develop and commercialise Lunesta in Japan

Sepracor signs an agreement with Eisai for the development and commercialisation of its sleep aid product Lunesta  in Japan


US-based Sepracor has signed an agreement with Japanese pharmaceutical firm Eisai for the development and commercialisation of Sepracor's sleep aid treatment Lunesta (eszopiclone) in Japan.

Per the agreement, Eisai will be responsible for completing the remaining clinical trials necessary for attaining marketing approval from the Japanese regulatory authorities, and contingent on regulatory approval, commercialisation of the product in Japan. Sepracor has said that the Japanese marketing application will be submitted in 2010/2011.

Sepracor will receive an initial milestone payment and subsequent payments upon accomplishment of various development, regulatory and pricing milestones, as well as royalties on product sales and compensation for providing the product's active ingredient.

Lunesta has been commercially available in the US since 2005 for the treatment of insomnia and posted sales of USD 566.8m in FY06. The sedative hypnotic market in Japan was valued at around USD 500m in 2006.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics